Gadoteridol

Also known as Gd-hpdo3a, Gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate, Gadolinium-HP-do3a, GD-HP-do 3a, Prohance, Prohance Multipack, SQ-32692

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance. Gadoteridol was first approved for use in the United States in 1992.